Iain A McNeish Division of Cancer, Department of Surgery and Cancer Imperial College London Biography Publications Institution JoVE Articles Iain A McNeish has not added a biography. If you are Iain A McNeish and would like to personalize this page please email our Author Liaison for assistance. Publications Weekly Dose-dense Chemotherapy in First-line Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Treatment (ICON8): Primary Progression Free Survival Analysis Results from a GCIG Phase 3 Randomised Controlled Trial Lancet (London, England). Nov, 2019 | Pubmed ID: 31791688 Prophylactic in Vivo Hematopoietic Stem Cell Gene Therapy with an Immune Checkpoint Inhibitor Reverses Tumor Growth in Syngeneic Mouse Tumor Models Cancer Research. Nov, 2019 | Pubmed ID: 31727629 Antitumor Activity of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib As Monotherapy in Patients with Platinum-sensitive, Relapsed, -mutated, High-grade Ovarian Cancer, and an Update on Safety International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. Nov, 2019 | Pubmed ID: 31685558 Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions Cells. 02, 2019 | Pubmed ID: 30813545 Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk Cancer Research. 02, 2019 | Pubmed ID: 30559148 Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma Cancer Discovery. 02, 2019 | Pubmed ID: 30425037 Mannose Impairs Tumour Growth and Enhances Chemotherapy Nature. 11, 2018 | Pubmed ID: 30464341 Methylation of All BRCA1 Copies Predicts Response to the PARP Inhibitor Rucaparib in Ovarian Carcinoma Nature Communications. 09, 2018 | Pubmed ID: 30266954 Rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology International Journal of Molecular Sciences. Aug, 2018 | Pubmed ID: 30134598 Copy Number Signatures and Mutational Processes in Ovarian Carcinoma Nature Genetics. 09, 2018 | Pubmed ID: 30104763 A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk Cancer Research. 09, 2018 | Pubmed ID: 30054336 Neoantigens in Ovarian Cancer: Embarrassment of Riches or Needles in a Haystack? Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. 11, 2018 | Pubmed ID: 29980529 Author Correction: CRISPR/Cas9-derived Models of Ovarian High Grade Serous Carcinoma Targeting Brca1, Pten and Nf1, and Correlation with Platinum Sensitivity Scientific Reports. Apr, 2018 | Pubmed ID: 29651149 RIPK3 Promotes Adenovirus Type 5 Activity Cell Death & Disease. 12, 2017 | Pubmed ID: 29238045 CRISPR/Cas9-derived Models of Ovarian High Grade Serous Carcinoma Targeting Brca1, Pten and Nf1, and Correlation with Platinum Sensitivity Scientific Reports. 12, 2017 | Pubmed ID: 29203787 Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (3rd Edition) Autophagy. Jan, 2016 | Pubmed ID: 26799652 Rethinking Ovarian Cancer II: Reducing Mortality from High-grade Serous Ovarian Cancer Nature Reviews. Cancer. Nov, 2015 | Pubmed ID: 26493647 Repeatability of Quantitative FDG-PET/CT and Contrast-enhanced CT in Recurrent Ovarian Carcinoma: Test-retest Measurements for Tumor FDG Uptake, Diameter, and Volume Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. May, 2014 | Pubmed ID: 24573555 Rethinking Ovarian Cancer: Recommendations for Improving Outcomes Nature Reviews. Cancer. Oct, 2011 | Pubmed ID: 21941283 Fibroblast Growth Factor 2-mediated Translational Control of IAPs Blocks Mitochondrial Release of Smac/DIABLO and Apoptosis in Small Cell Lung Cancer Cells Molecular and Cellular Biology. Nov, 2003 | Pubmed ID: 14560006 Поколение ортотопических опухолей поджелудочной железы и Ex vivo Характеристика опухоли-проникновения T клеточной цитотоксичности Sarah Spear1,2, Iain A McNeish1, Melania Capasso2,3 1Division of Cancer, Department of Surgery and Cancer, Imperial College London, 2Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, 3German Center for Neurodegenerative Diseases (DZNE) JoVE 60622 Ricerca sul cancro
Поколение ортотопических опухолей поджелудочной железы и Ex vivo Характеристика опухоли-проникновения T клеточной цитотоксичности Sarah Spear1,2, Iain A McNeish1, Melania Capasso2,3 1Division of Cancer, Department of Surgery and Cancer, Imperial College London, 2Centre for Cancer and Inflammation, Barts Cancer Institute, Queen Mary University of London, 3German Center for Neurodegenerative Diseases (DZNE) JoVE 60622 Ricerca sul cancro